Abstract | BACKGROUND: OBJECTIVES: METHODS: We retrospectively reviewed the medical records of 312 patients who visited The University of Tokyo Hospital between January 2007 and December 2017 for nontuberculous mycobacterial pulmonary disease. Seventy-six patients with MAC-PD who were treated with combination chemotherapy for the first time were analyzed in this study. RESULTS:
Ethambutol was discontinued because of visual symptoms in 13 patients (17%), 7 of whom were diagnosed with ethambutol ocular neuropathy. The dose per body weight was significantly higher in patients who developed ocular neuropathy than in those who did not (15.4 mg/kg/d vs. 12.5 mg/kg/d, respectively; p = 0.048). We assigned patients to higher or lower dose groups according to the median dose of 12.5 mg/kg/d. Although ocular neuropathy developed in 6 out of 38 patients in the higher dose group, ocular neuropathy developed in 1 out of 38 patients in the lower dose group (16% vs. 3%, respectively; p = 0.038). The failures of sputum culture conversion and radiological improvement were not significantly different between the two groups (p = 0.638 and 0.305, respectively). Macrolide resistance developed in one patient per group during follow-up (3% per group, p = 0.945). CONCLUSIONS:
|
Authors | Takahiro Ando, Hidenori Kage, Yoko Matsumoto, Koichi Zokumasu, Takahide Nagase |
Journal | Respiratory investigation
(Respir Investig)
Vol. 59
Issue 6
Pg. 777-782
(Nov 2021)
ISSN: 2212-5353 [Electronic] Netherlands |
PMID | 34389250
(Publication Type: Journal Article, Randomized Controlled Trial)
|
Copyright | Copyright © 2021. Published by Elsevier B.V. |
Chemical References |
- Anti-Bacterial Agents
- Antitubercular Agents
- Macrolides
- Ethambutol
- Clarithromycin
- Rifampin
|
Topics |
- Anti-Bacterial Agents
(therapeutic use)
- Antitubercular Agents
(adverse effects)
- Clarithromycin
(therapeutic use)
- Drug Resistance, Bacterial
- Drug Therapy, Combination
- Ethambutol
(adverse effects)
- Humans
- Lung Diseases
(drug therapy)
- Macrolides
- Mycobacterium avium Complex
- Mycobacterium avium-intracellulare Infection
(drug therapy)
- Retrospective Studies
- Rifampin
(therapeutic use)
- Toxic Optic Neuropathy
|